Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent

Investigative Radiology

Volumn 44, Issue 3, 2009, Pages 146-150

  Katoh, Marcus ^a,b   Haage, Patrick ^c   Wiethoff, Andrea J ^d   Gunther, Rolf W ^a   Bucker, Arno ^b   Tacke, Josef ^e   Spuentrup, Elmar ^f  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c HELIOS KLINIKUM WUPPERTAL   (Germany)

^d Epix Pharmaceuticals   (United States)

^e Klinikum Passau   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Deep vein thrombosis; Fibrin specific contrast agent; Interventional radiology; Molecular MRI

Indexed keywords

CONTRAST MEDIUM; EP 2104 R; FIBRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON OCCLUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FOGARTY CATHETER; MECHANICAL THROMBECTOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; SWINE;

EID: 66749154095     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318195886d     Document Type: Article

References (26)

1. Tacke J, Vorwerk D, Bucker A, et al. Experimental treatment of early chronic iliac vein thrombosis with a modified hydrodynamic thrombectomy catheter: preliminary animal experience. J Vasc Interv Radiol. 1999;10:57-63.
2. Sharafuddin MJ, Hicks ME. Current status of percutaneous mechanical thrombectomy. Part II. Devices and mechanisms of action. J Vasc Interv Radiol. 1998;9:15-31.
3. Dick A, Neuerburg J, Schmitz-Rode T, et al. Declotting of embolized temporary vena cava filter by ultrasound and the Angiojet: comparative experimental in vitro studies. Invest Radiol. 1998;33:91-97.
4. Grimm J, Muller-Hulsbeck S, Heller M. Comparison of the mechanical thrombectomy efficacy of the Amplatz thrombectomy device and the Cragg thrombolytic brush in vitro. Invest Radiol. 2001;36:204-209.
5. Muller-Hulsbeck S, Brossmann J, Jahnke T, et al. Mechanical thrombectomy of major and massive pulmonary embolism with use of the Amplatz throm-bectomy device. Invest Radiol. 2001;36:317-322.
6. Qian Z, Kvamme P, Raghed D, et al. Comparison of a new recirculation thrombectomy catheter with other devices of the same type: in vitro and in vivo evaluations. Invest Radiol. 2002;37:503-511.
7. Birnbaum Y, Luo H, Nagai T, et al. Noninvasive in vivo clot dissolution without a thrombolytic drug: recanalization of thrombosed iliofemoral arteries by transcutaneous ultrasound combined with intravenous infusion ofmicrobubbles. Circulation. 1998;97:130-134.
8. Rosenschein U, Gaul G, Erbel R, et al. Percutaneous transluminal therapy of occluded saphenous vein grafts: can the challenge be met with ultrasound thrombolysis? Circulation. 1999;99:26-29.
9. Belcaro G, Nicolaides AN, Cesarone MR, et al. Shock waves (SW) noninvasive extracorporeal thrombolysis treatment (NISWT). Angiology. 1999;50: 707-713.
10. Tomasian A, Lohan DG, Laub G, et al. Noncontrast 3D steady state free precession magnetic resonance angiography of the thoracic central veins using nonselective radiofrequency excitation over a large field of view: initial experience. Invest Radiol. 2008;43:306-313.
11. Porter JM, Moneta GL. Reporting standards in venous disease: an update. International consensus committee on chronic venous disease. J Vasc Surg. 1995;21:635-645.
12. Califf RM, Fortin DF, Tenaglia AN, et al. Clinical risks of thrombolytic therapy. Am J Cardiol. 1992;69:12A-20A.
13. Sirol M, Fuster V, Badimon JJ, et al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005;112:1594-1600.
14. Botnar RM, Buecker A, Wiethoff AJ, et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110:1463-1466.
15. Spuentrup E, Buecker A, Katoh M, et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation. 2005;111:1377-1382.
16. Spuentrup E, Fausten B, Kinzel S, et al. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation. 2005;112:396-399.
17. Spuentrup E, Katoh M, Buecker A, et al. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol. 2007;42:586-595.
18. Spuentrup E, Katoh M, Wiethoff AJ, et al. Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. Am J Respir Crit Care Med. 2005;172:494-500.
19. Katoh M, Haage P, Spuentrup E, et al. A porcine deep vein thrombosis model for magnetic resonance-guided monitoring of different thrombectomy procedures. Invest Radiol. 2007;42:727-731.
20. Botnar RM, Perez AS, Witte S, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004;109:2023-2029.
21. Haage P, Tacke J, Bovelander J, et al. Prototype percutaneous thrombolytic device: preclinical testing in subacute inferior vena caval thrombosis in a pig model. Radiology. 2001;220:135-141.
22. Spuentrup E, Buecker A, Stuber M, et al. MR-venography using high resolution true-FISP. Rofo. 2001;173:686-690.
23. Maki JH, Chenevert TL, Prince MR. The effects ofincomplete breath-holding on 3D MR image quality. JMagn Reson Imaging. 1997;7:1132-1139.
24. Overoye-Chan K, Koerner S, Looby RJ, et al. EP-2104R: a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. JAm Chem Soc. 2008;130:6025-6039.
25. Spuentrup E, Buecker A, Meyer J, et al. Navigator-gated free-breathing 3D balanced FFE projection renal MRA: comparison with contrast-enhanced breath-hold3DMRAinaswinemodel.MagnResonMed.2002;48:739-743.
26. Spuentrup E, Botnar RM, Wiethoff AJ, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008;18:1995-2005.